Log in or register to see all Alerts
New HTA Decisions in France
December 2021
Drug name
COSENTYX® (secukinumab)
Novartis Pharma SAS
Decision date
Therapeutic area
Skin conditions
Therapeutic sub area
Official notice date
Reimbursement %
Decision (SMR)
Decision (ASMR)
No improvement (V)
COSENTYX® is indicated for the treatment of adolescents and children from 6 years of age with severe chronic plaque psoriasis defined as: • an insufficient response, contraindication or intolerance to at least two treatments among non-biological systemic treatments and phototherapy; • and a widespread form and/or significant psychosocial repercussions.
Decision Type
New technology assessment
Considering the potential impact of the condition on quality of life, the good benefit-risk profile of COSENTYX®, the limited alternatives available, the place of COSENTYX® in the therapeutic strategy, and the unlikely impact of COSENTYX® on public health, the committee considered the actual benefit of COSENTYX® to be ‘important’ in severe disease – proposing a reimbursement rate of 65% – and insufficient to justify reimbursement in other areas of the Marketing Authorisation. The 75 mg presentation of the drug was considered to provide no improvement in actual benefit (ASMR V) compared to the presentations already listed.